Different polymerization techniques as particle formation processes for ciprofl oxacin-loaded poly (butyl cyanoacrylate) nanoparticles (CfH-PBCN) were evaluated to choose the most appropriate in terms of the resulting nanoparticles characteristics suitable for parenteral administration. The formulations prepared by the selected technique were considered concerning size, size distribution, surface charge, loading effi ciency, drug release. The mechanism of drug immobilization was also studied. Emulsion polymerization using 0.1 M HCl as an acidifying medium and Pluronic F68 as an emulsifi er was found to be the best technique, leading to nanoparticles with a mean diameter below 300 nm, narrow size distribution, and a high drug payload of between 61-81 %. Analytical techniques (FTIR, GPC, XRD and 1 H NMR) are consistent with a strong covalent interaction between the drug and the polymer matrix of the nanoparticles. It is proposed that CfH is involved in the initiation of the polymerization process resulting in a modifi cation of CfH molecule that could reduce its susceptibility to effl ux in Gram-positive bacteria and eukaryotic cells. The antimicrobial activity of CfH-PBCN against Bacillus subtilis 3562 and Escherichia coli K12 is similar to that of the free drug and confi rms that this activity is largely unaffected by the drug's association with the polymer nanoparticles.
Introduction
Ciprofl oxacin
(1-cyclopropyl-6-fl uoro-4-oxo-7-piperazin-1-yl-quinoline-3-carboxylic acid, Figure 1 is a second generation fl uoroquinolone antibiotic, with a broad spectrum of activity against wild-type Gram-positive and Gram-negative organisms. Ciprofl oxacin (CfH) is among the most effective antibiotics used clinically [1] , and has become the drug of choice for a variety of topical applications [2] . However, due to its relatively short intracellular residence time, CfH is considered less effective than other fl uoroquinolones, such as pefl oxacin and ofl oxacin, in some intracellular infections [3] . The recognition of CfH by the effl ux transporters needs modulation in order to optimize its pharmacological profi le. To overcome these disadvantages two different approaches have been proposed:
i. Chemical modifi cation of the CfH molecule [4, 5] .
ii. Targeting the intracellular compartment using suitable drug delivery systems (DDS) able to prolong the intracellular residence time inside infected cells and to enhance the drug bioavailability.
A variety of DDS [6] [7] [8] [9] [10] [11] [12] [13] has been studied in order to improve the specifi city of the drug, to reach the sites where pathogens are harboured and to enhance the drug effi ciency, including reducing bacterial biofi lm formation [14] . The effectiveness of different poly (alkyl cyanoacrylate) (PACA) nanoparticles [15] [16] [17] , as drug carriers for CfH, was investigated in an attempt to enhance its bioavailability in infected cells and hence improve its therapeutic effi ciency. Although promising results were obtained for antibacterial activity in vitro, the inclusion of CfH into PACA nanoparticles resulted in incomplete eradication of Salmonella persisting in organs of the mononuclear phagocyte system [18] , most probably due to some non-dividing intracellular bacteria with less susceptibility to antibiotic treatment [19] .
In the present work, different polymerization techniques for the preparation of ciprofl oxacin loaded poly (butyl cyanoacrylate) nanoparticles (CfH-PBCN) were analyzed to identify the most suitable in terms of the physicochemical properties of the resulting nanoparticles appropriate for parenteral administration. The formulations prepared by the selected polymerization technique were studied with respect to particle size and distribution, loading effi ciency, and drug release. The mechanism of drug-polymer interaction was established, and the antibacterial activity of the chosen formulation was evaluated in vitro.
Materials and Methods

Materials
Ciprofl oxacin, Pluronic F68, and citric acid as monohydrate were purchased from Sigma-Aldrich. Normal butyl-2-cyanoacrylate (n-BCA) was obtained from Specialty Polymers Ltd., Bulgaria, Dextran 40 (mol. wt. 40 000 g/mol) from Pharmachim, Bulgaria and DMSO-d 6 from CortecNet (France).
Other chemicals were of laboratory grade purity and used as obtained.
Preparation of ciprofl oxacin-loaded nanoparticles
The CfH-PBCN were prepared by several techniques:
Dispersion polymerization: Dispersion polymerization was carried out in an acidifi ed (citric acid, 0.2% w/v) aqueous medium, containing dextran 40 (0.8 % w/v) as a colloid stabilizer and ciprofl oxacin (0.1-0.4 mg/ml). The monomer was added carefully to the above aqueous medium under magnetic agitation. Polymerization was accomplished with or without addition of 4% v/v acetone in the polymerization medium.
Polymerization started instantly and proceeded for ca. 3.5 h at room temperature. After the polymerization process ended, the pH of the resulting colloidal suspension was adjusted to a value of 5.5 using 1 N NaOH. 
Physicochemical characterization
Dynamic light scattering and electrophoretic mobility measurements: A Zetasizer Nano ZS (Malvern Instruments Ltd., UK) was used for particle size, size distribution and zeta potential measurements by dynamic light scattering and laser Doppler electrophoresis, respectively. Before analyses, the samples were appropriately diluted with deionized water. Size measurements were accomplished at a light scattering angle of 173° at 25 °C in a 12 mm square polystyrene cuvette (Sarstedt, Germany). The zeta potential measurements were performed at a light scattering angle of 17° at 25 °C, using a disposable capillary cell (DTS 1060, Malvern).
Scanning electron microscopy analysis: The morphology of unloaded and CfH-loaded nanoparticles was examined using a Philips SEM 515 (The Netherlands) scanning electron microscope, operated at 25 kV accelerating voltage. Samples were deposited on cover glasses, dried and then coated with a gold-palladium thin fi lm using a 3C7620 Sputter Coater (Quorum Technologies Ltd., UK).
Fourier transforms infrared (FTIR) spectroscopy characterization:
Unloaded and CfH-loaded nanoparticles, free CfH, and a physical mixture of unloaded nanoparticles and CfH were analyzed by FTIR spectroscopy. Spectra were recorded on KBr discs using a Varian Resolutions Pro spectrometer with a resolution of 2 cm -1 in the 4000-400 cm -1 spectral region.
Gel Permeation Chromatography: Molecular weight and molecular weight distributions of loaded and unloaded nanoparticles were determined by gel permeation chromatography (GPC). A Waters chromatographic system equipped with a differential refractometer M410, with a set of Phenogel 100 Ǻ and Phenogel 10000 Å columns (Phenomenex), used simultaneously and calibrated with polystyrene standards was used. Tetrahydrofuran (THF) was used as a mobile phase, with a fl ow rate of 1.0 ml/min at 40 °C. Samples were dissolved in THF at a concentration of 4 mg/ml, and portions of 100 μl of the solutions were injected into the chromatographic system. Data collection and processing were carried out using the Clarity software (DataApex) UV-visible spectroscopy characterization: UV-Vis Spectroscopic measurements were performed on free and nanoparticle associated CfH in deionized water (pH 5) on a UV-1600 PC Spectrophotometer (VWR International Europe, Belgium), equipped with 10-mm quartz cells.
Entrapment effi ciency:
Samples of CfH-loaded nanoparticles were centrifuged at 15000 rpm for 1 h at 4 °C in a MIKRO 220R centrifuge (Hettich ZENTRIFUGEN, Germany). The supernatants were analyzed by UV-visible spectroscopy, and the concentration of free drug in the supernatant was determined by direct spectrophotometric analysis. Entrapment effi ciency (EE) was calculated using the equation: EE (%) = (initial drug concentration − concentration in supernatant)/ initial drug concentration) ×100.
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In vitro drug release study One ml of intact CfH-loaded PBCN (CfH 0.4 mg/ml) was introduced into a dialysis tube (MWCO 3 500 g/mol) and sealed. This dialysis tube was put into a 50 ml Erlenmeyer fl ask with 25 ml of phosphate buffered saline (PBS, pH 5.5). Release tests were performed at 37±0.5 °C under mild stirring. At predetermined times, 1 ml aliquots of the release medium were taken and subsequently replaced with fresh medium. Each aliquot was assayed for CfH using UV-visible spectroscopy at 277 nm.
NMR analysis
1 H NMR spectra, recorded on a Bruker Avance III 400 spectrometer at a temperature of 25 °C in dimethyl sulfoxide-d 6 (DMSO-d 6 ) solution were referenced to the solvent resonance peak at 2.49 ppm. Proton registered diffusion-ordered NMR ( 1 H DOSY) experiments were acquired using a 2D sequence for diffusion measurements, with stimulated echo and bipolar gradient pulses (stebpgp1s, Bruker library) as the experimental conditions (amount of the solute and the solvent, temperature, air fl ow, no sample rotation) were kept constant. In each experiment, 32 spectra of 32 k data points were collected, with values for the duration of the magnetic fi eld pulse gradients () of 4 and 2.8 ms, diffusion times (Δ) of 200 and 150 ms for nanoparticles (unloaded and drug-loaded) and free CfH, respectively. The pulse gradient (g) was incremented from 2 to 95% of the maximum gradient strength in a linear ramp. All spectra were processed using the Bruker Topspin software package (version 3.2). The diffusion coeffi cients (D) were obtained by measuring the signal intensity at more than one place in the spectra. At least two different measurements were performed for the determination of each diffusion coeffi cient. ) was used as an internal reference for the diffusion measurements.
X-ray powder diffraction
X-ray powder diffraction data were collected on a PANAlytical X'Pert Pro diffractometer using Ni fi ltered Cu K ( = 1.5418 Å) in fl at plate / geometry. Data were acquired over the 2 range 3 to 70°, in steps of 0.0334°, with an effective counting time of 200 s per step. Data were calibrated with an external LaB 6 standard.
Antibacterial activity
The antibacterial activity of free CfH, unloaded and CfH loaded nanoparticles was tested in vitro against Gram-positive Bacillus subtilis 3562 and facultative anaerobic Gram-negative Esherichia coli K12, using the agar disk diffusion method, and an assay based on the reduction of viable bacterial cells after exposure to the tested compounds. The strains obtained from the culture collection of the Bulgarian National Bank of Industrial Microorganisms and Cell Cultures were cultured in Luria-Bertani (LB) medium.
Agar disk diffusion method:
The overnight bacteria cultures from tested strains were prepared in a liquid LB medium. Cell reduction (%) = (1-Test sample (CFU/ml)/Control (CFU/ ml)) ×100 [20] . Samples of untreated bacterial cells were used as controls. The measurements were made in duplicate.
Results and Discussion
The most frequently used method for preparation of PACA Table 1 ). The increase of the drug equilibrium concentration leads to an increase in PDI. The extremely high dispersity of CfH-PBCN formulations make them inappropriate for medical applications, as better targeting can be achieved by monodisperse systems, since only particles of specifi c sizes are accumulated in the target tissues.
No clear dependence of drug entrapment and polydispersity on the presence or absence of acetone in the polymerization system was observed, although it is known that acetone is able to diminish the aggregation of the obtained polymer chains by increasing the monomer diffusion from monomer droplet to aqueous phase [17] . Further, experiments using the dispersion polymerization method were therefore discontinued.
Nanoparticles prepared by interfacial polymerization have a satisfactory mean diameter, but the maximum drug loading of 0.010 mg/mg is reached at around 0.3 mg/ml concentration of CfH in the medium (Table 2) . Furthermore, the PDI increases above this equilibrium drug concentration. These unfavorable fi ndings indicate that interfacial polymerization is unsuitable for the preparation of CfH-PBCN for parenteral administration.
The mean diameters of the synthesized unloaded and ciprofl oxacin-loaded nanoparticles prepared using emulsion polymerization were found to be greater than 311 nm, when citric acid was used as an acidifying agent ( Table 3 Entrapment effi cacy increases with increasing equilibrium drug concentration up to around 0.9 mg/ml ciprofl oxacin (Table 4) . This is refl ected in an increase in drug loading capacity, with the maximum value of 0.041 mg/mg attained at Although an acid, the CfH molecule shows amphoteric behavior in aqueous solutions due to the acid-base interaction between the piperazine basic nitrogen and the carboxylic group [22] .
This acid-base interaction gives a weak basic character to the drug and the possibility of initiating the polymerization of cyanoacrylates via zwiterion formation. Analogous zwitterionic initiation of n-BCA polymerization by imino moieties in 5-fl uorouracil molecules has been reported previously [23, 15] assumed interaction between CfH and isobutylcyanoacrylate during the polymerization process when preparing CfHloaded poly (isobutyl cyanoacrylate) nanoparticles, leading to initiation of polymerization through a zwitterionic pathway.
The involvement of CfH in the polymerization of 2-ethylbutyl cyanoacrylate during the formation of poly (ethylbutyl cyanoacrylate) nanoparticles was described by Page-Clisson et al. [17] . However, these authors proposed an anionic mechanism of initiation of the polymerization of 2-ethylbutyl cyanoacrylate based on the signifi cantly smaller Mw found for CfH-loaded nanoparticles.
It is important to note that Beyer et al. [24] suggested that the introduction of hydrophobic substituents in position C-7 (piperazine ring) of fl uoroquinolones may reduce their susceptibility to effl ux in Gram-positive organisms.
Recently, Marquez et al. [5] demonstrated that addition of a bulky, lipophilic side chain on the CfH molecule at the same position (N-substituted) resulted in a markedly modifi ed pharmacological profi le of the drug, due to its reduced susceptibility to effl ux in Gram-positive bacteria and eukaryotic cells and an increased accumulation in eukaryotic cells, without affecting either subcellular distribution or intracellular activity. Other authors have also considered the structural differences in fl uoroquinolones, especially overall molecular hydrophobicity and bulkiness of the C-7 substituent as factors infl uencing the effi ciency of effl ux [25] [26] [27] [28] [29] .
It can be argued that the covalent bond between the NH of CfH and the hydrophobic poly (butyl cyanoacrylate) chain, formed during the initiation process in the present study is a similar modifi cation of the CfH molecule and could act in a similar way in reducing susceptibility to effl ux in Grampositive bacteria and eukaryotic cells.
The UV-visible spectra of free CfH and CfH-PBCN are shown in fi gure 4а. The inclusion of the CfH into the nanoparticles substantially changes its absorption spectrum. Three distinct absorption bands at 216, 277 and 315 nm are seen for free CfH. The latter two bands are greatly reduced in intensity in CfH-PBCN and are consistent with a chemical interaction between the drug molecule and the polymer matrix.
The FT-IR spectra of unloaded and ciprofl oxacin-loaded PBCN are compared with that of the free drug and a physical mixture of the CfH and unloaded nanoparticles in fi gure 4b. In the spectrum of the free drug, the absorption bands at 1616.17 cm -1 and 1724 cm -1 are attributed to the symmetric stretching of C=O of pyridone and carboxylic moieties, respectively [30] , while that at 1588.42 cm -1 is due to the C=C stretching mode. The stretching vibration at 3403 cm -1 is assigned to the OH in the carboxylic group. C-N stretching is seen at 1284.88 cm -1 . The absorption band at 1035 cm -1 is assigned to the C-F stretching vibration, while the vibration at 721 cm -1 indicates the absorption peak of secondary amine (-NH).
The FT-IR spectrum of the unloaded nanoparticles shows characteristic bands for the poly(butyl cyanoacrylate): the CH 3 asymmetric and symmetric vibration at 2959 cm -1 and 2878 cm -1 , respectively and asymmetric CH 2 at 2934 cm -1 , CN stretching at 2246 cm -1 , C=O stretching at 1751 cm -1 , asymmetric and symmetric C-O-C stretches at 1257 and 1018 cm -1 , respectively, C-CN band at 1169 cm -1 and OH at 3479.31 cm -1 included in the polymer chain from water during initiation of polymerization.
The FT-IR spectrum of the physical mixture of unloaded PBCN and free CfH shows the characteristic bands for both compounds. In contrast, the characteristic bands of the CfH molecule are greatly reduced in intensity compared to the physical mixture in the FT-IR spectrum of CfH-PBCN. All bands characteristic for poly (butyl cyanoacrylate) are visible. The characteristic band assigned to quinolones at 1627.87 cm -1 is clearly observed, confi rming the presence of CfH molecules in the polymer matrix of nanoparticles. The disappearance of the absorption band at 721 cm -1 suggests the possible involvement of the imino group in drug-polymer interaction. values close to 7 (isoelectric point of the molecule) is low [33] .
As fi gure 7 shows, the nanoparticles release only about 19.9% of their drug content. This drug release profi le is indicative of a strong drug-polymer interaction.
A similar release profi le of CfH associated to poly (ethylbutyl cyanoacrylate) nanoparticles was described by Page-Glisson et al. [17] . The authors reported no signifi cant drug release in phosphate-buffered saline, or very slow drug release of 22.3% (Table 5 ) and 81% for E. coli K12 (Table 6) . 
